
Please try another search
Abbott Laboratories (NYSE:ABT) shares are gaining over 4% in mid-day trading Tuesday after the company entered into a consent decree with the FDA on steps to resume production at its troubled infant formula plant in Sturgis, Michigan. The shutdown of the plant, due to suspected links to infant illnesses, has contributed to the national crisis of infant formula shortages.
"Our number one priority is getting infants and families the high-quality formulas they need, and this is a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage," Abbott CEO Robert Ford commented.
The plant is to restart within two weeks after the FDA confirms the initial requirements for start-up have been met.
Once authorized, Abbott said it would begin production of EleCare, Alimentum and metabolic formulas first and then begin production of Similac and other formulas.
A thorough investigation by FDA, Centers for Disease Control and Prevention (CDC) and Abbott has revealed there is no conclusive evidence to link Abbott's formulas to these infant illnesses.
The consent decree between Abbott and the FDA is subject to court approval.
By Scott Kanowsky Investing.com -- European markets opened in the green on Tuesday, spurred on by a lift in sentiment in Asia, where stocks jumped on news that China will ease...
By Peter Nurse Investing.com - European stock markets are expected to open mixed Tuesday as German consumer confidence sees another drop while the summit of Group of Seven leaders...
By Zhang Mengying Investing.com – Asia Pacific stocks were mostly down on Tuesday morning after Wall Street fell and oil prices rose on tight supply concerns. Japan’s Nikkei 225...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.